Literature DB >> 14657181

Angiotensin II blocks nicotine-mediated neuroprotection against beta-amyloid (1-42) via activation of the tyrosine phosphatase SHP-1.

Seán Shaw1, Merouane Bencherif, Mario B Marrero.   

Abstract

We showed recently that nicotine activates the growth-promoting enzyme Janus kinase 2 (JAK2) in PC12 cells and that preincubation of these cells with the JAK2-specific inhibitor AG-490 blocked the nicotine-induced neuroprotection against beta-amyloid (1-42) [Abeta (1-42)]. These results provided direct evidence for linkage between JAK2 and the alpha7 nicotinic acetylcholine receptor-induced neuroprotection in PC12 cells. We also showed that preincubation with angiotensin II (Ang II), functioning via the angiotensin II type 2 (AT2) receptor, blocked both the nicotine-induced activation of JAK2 and its neuroprotection against Abeta (1-42). Recently growth-inhibitory effects of the AT2 receptor have been reported to be mediated by the activation of protein tyrosine phosphatases (PTPases) and that AT2 receptor stimulation is associated with a rapid activation of the PTPase SHP-1 (the cytoplasmic tyrosine phosphatase that contains Src homology 2 domains), a negative regulator of JAK2 signaling. Therefore, the potential biological significance of AT2 receptor-induced effects on both the nicotine-induced activation of JAK2 and its neuroprotection against Abeta (1-42) led us to investigate whether SHP-1 activation could be involved in this process. We found that Ang II induced the activation of SHP-1 and that an antisense against SHP-1 not only augmented the nicotine-induced tyrosine phosphorylation of JAK2 but also blocked the Ang II neutralization of the nicotine-induced neuroprotection. These results demonstrate that nicotine-induced tyrosine phosphorylation of JAK2 and neuroprotection against Abeta (1-42) in PC12 cells are blocked by Ang II via AT2 receptor-induced activation of SHP-1.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14657181      PMCID: PMC6741058     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  8 in total

Review 1.  Application of alpha7 nicotinic acetylcholine receptor agonists in inflammatory diseases: an overview.

Authors:  Mario B Marrero; Merouane Bencherif; Patrick M Lippiello; Rudolf Lucas
Journal:  Pharm Res       Date:  2010-09-22       Impact factor: 4.200

Review 2.  The Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target.

Authors:  U Muscha Steckelings; Robert E Widdop; Edward D Sturrock; Lizelle Lubbe; Tahir Hussain; Elena Kaschina; Thomas Unger; Anders Hallberg; Robert M Carey; Colin Sumners
Journal:  Pharmacol Rev       Date:  2022-10       Impact factor: 18.923

Review 3.  Alpha7 nicotinic acetylcholine receptor: a link between inflammation and neurodegeneration.

Authors:  Concepcion Conejero-Goldberg; Peter Davies; Luis Ulloa
Journal:  Neurosci Biobehav Rev       Date:  2007-11-28       Impact factor: 8.989

Review 4.  The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation.

Authors:  W J de Jonge; L Ulloa
Journal:  Br J Pharmacol       Date:  2007-05-14       Impact factor: 8.739

5.  Nicotine inhibits ethanol-induced toxicity in cultured cerebral cortical cells.

Authors:  Yousef Tizabi; Kebreten F Manaye; Duane T Smoot; Robert E Taylor
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

6.  Renin-Angiotensin system hyperactivation can induce inflammation and retinal neural dysfunction.

Authors:  Toshihide Kurihara; Yoko Ozawa; Susumu Ishida; Hideyuki Okano; Kazuo Tsubota
Journal:  Int J Inflam       Date:  2012-03-22

7.  Roles of Brain Angiotensin II in Cognitive Function and Dementia.

Authors:  Masaki Mogi; Jun Iwanami; Masatsugu Horiuchi
Journal:  Int J Hypertens       Date:  2012-12-11       Impact factor: 2.420

Review 8.  Neuroimmunity, drugs of abuse, and neuroAIDS.

Authors:  Tricia H Burdo; Simon N Katner; Michael A Taffe; Howard S Fox
Journal:  J Neuroimmune Pharmacol       Date:  2006-03       Impact factor: 7.285

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.